2nd World Congress on

Osteoporosis and Bone Health

Theme: Advances in the evaluation and treatment of Bone Health

Event Date & Time

Event Location

Madrid, Spain

18 years of lifescience communication

Previous Conference Performers / Professionals From Around The Globe

Conference Speaker

Todd Kuiken

Northwestern University

Conference Speaker

C. Kent Kwoh

University of Arizona Arthritis Center

Conference Speaker

Homero Ramirez

Universidad Autonoma Agraria Antonio Narro

Conference Speaker

Giovanni Abatangelo

University of Padua

Conference Speaker

Tesfaye Hordofa Leta

University of Bergen

Conference Speaker

Yasser El Miedany

Kings College London

Conference Speaker

Douglas E Garland

Joint Replacement Center

Conference Speaker

Laurence A. Bradley

University of Alabama at Birmingham

Conference Speaker

Nicolas Pavlos Omorphos

University College London

Conference Speaker

Mohamed Albarouni

Bonn University

Conference Speaker

Margaret Wislowska

Centralny Szpital Kliniczny MSW

Conference Speaker

Jasvinder A. Singh

University of Alabama at Birmingham (UAB)

Tracks & Key Topics

Osteoporosis Conference 2019

About Conference

In Europe, the disability due to osteoporosis is greater than that caused by and is comparable or greater than that lost to a variety of chronic noncommunicable diseases, such as rheumatoid arthritis, asthma and high blood pressure related heart disease. Based on WHO diagnostic criteria approximately 22 million women and 5.5 million men aged between 50-84 years of age are estimated to have osteoporosis in the EU. Due to changes in population demography the number of men and women with osteoporosis in the EU will rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The annual number of fractures in the EU will rise from 3.5 million in 2010 to 4.5 million in 2025, corresponding to an increase of 28%. 
Orthopaedists, patients and health care providers consider the improvement of bone health to prevent osteoporosis and fractures. According to the statistics mentioned above, EuroSciCon is set to organize 2nd World Congress on Osteoporosis and Bone Health scheduled during April 22-23, 2019 at Madrid, Spain with a view to promote awareness and enhance research aiming in developing solutions for the challenges encountered.
The upcoming Osteoporosis Conference 2019 will be focusing upon the theme Advances in the evaluation and treatment of Bone Health to help improve communication and knowledge among professionals, community and to provide a platform for international colleagues, delegates to establish corporations and stimulating presentations, new ideas and thoughts and update modern procedures, preventive precautions to improve bone health of the individuals. This two day conference also provides a place for both academic experts and professional business specialists with inter-disciplinary/multi-disciplinary benefits related to Osteoporosis and Bone Health. The Conference will have space for institutions and/or companies to present their services, products, innovations and research results.
We are looking forward to welcoming you and spending valuable time in Madrid, Spain.
What you'll get:
Get deep and deeper than ever into the bone health research and new ideas with 2 full days of expert keynotes sessions, plenaries talk, workshops, poster sessions, symposiums, debates and group discussions.
Develop a plan of action and long-lasting terms with new policies that can be applicable to your association/society, institutions, a professional world for better improvements and development.
Get learns new emerging technologies, the latest trends and success strategies around the bone health research.
Network with expert peers, medical leaders and experts and get the insights you need to move onward for better advancement and development.
Get access to attentive and challenging debates.
Get engaged in an interactive environment on the important issues.
Target Audience:
The conference is open to all the professionals related to bone health research which includes but not limited to Internists
Family Doctors
Nurses and other Allied Health Professionals, Industry Experts, Researchers and Students.
Abstract submissions are now open for Key Note Forum, Oral performances, Panel conversation and scientific posters presentation within the designed track list (conference highlights) and also papers on other related topics that not listed are welcome if they meet the scope of the conference. We are excited and expecting our conference theme will inspire a number of research centres, institutions and organizations to gather at this International Academic and Business Forum. 

Sessions & Tracks

Track 1: Osteoporosis

Osteoporosis is a condition influencing a large number of individuals around the world. It is portrayed by low bone mass and structural disintegration of bone tissue, prompting upgraded bone fragility and consequent increase in fracture risk. The commonest breaks in osteoporosis are spine, hip and wrist cracks. In European nations the predominance of osteoporosis has been expanding from the most recent couple of years. Besides, expanding interest for portable and hand held devices for the analysis of osteoporosis and osteopenia add fuel to the development of the market. In Europe 22 million women and 5.5 million men are influenced with osteoporosis. The global osteoporosis drug market was esteemed at US$8.4 billion of every 2013 and is relied upon to be esteemed at US$8.9 billion by 2020. The global osteoporosis drug market is conjecture to develop at a 1.2% during the forecast period.            

Osteoporosis Conferences | Rheumatology Conferences | Osteopenia | Osteoporosis Assistive Devices | Osteoporosis Market | Osteoporosis Risk Factors

Track 2: Bone Health

Generally most of the people are unaware that bone is a metabolically active tissue. Every day old bone is broken down (bone resorption) and new bone is formed (bone arrangement). Adolescence is an especially essential time for bone health as it is the period to generate the greatest amount of bone and achieve peak bone mass (PBM). People with a low PBM are at higher danger of osteoporosis and fractures later. Insufficient energy intake during adolescence may bring about inability to acquire adequate PBM. Furthermore, energy restriction and/or low energy availability can decrease bone health thus increase the risk of bone injuries. In Europe, the increasing health conscious population and their tendency towards healthy food and beverages is driving the market for bone and joint health. The global bone densitometers market was esteemed at USD 777.9 million out of 2012 and is relied upon to develop at a CAGR of 3.3% from 2013 to 2019, to come to an expected estimation of USD 908.5million out of 2019.

Bone Densitometers | Bone Grafts | Bone Health Conferences | Bone Health Meetings | Orthopaedics Bone Health Clinics

Track 3: Physiotherapy and Pain Management

Physical therapy and exercise are perhaps the most mainstream of all types of pain and its management. The original nature of bone in people life may affected by the osteoporosis and fractures, to treat osteoporosis and fractures in the people, physiotherapy including manual procedures and exercise mediations are been considered. What's more, these medications are best and financially achievable to the osteoporosis and fractures patients. Physiotherapy is basically the specialty of diagnosing and treating wounds or diseases by using generally physical strategies, for example, rub, warm treatment, mobilisation and so forth. Physiotherapy envelops all territories of the life expectancy from newborn children to the elderly in zones, for instance musculoskeletal, orthopedics, rheumatology, respiratory, neurology, sports injuries and women's/men's prosperity. Every year 25,000 individuals in the Spain have vertebral breaks identified with their osteoporosis and numerous are alluded for physiotherapy to enable them to recoup after their fracture. The worldwide physiotherapy market will develop at an enduring rate and post a CAGR of over 6% amid the period 2017-2022.

Pain Management Conferences| Rehabilitation Centres | Physiotherapy Techniques | Occupational Therapy | Exercise Physiology

Track 4: Musculoskeletal Disorders

Musculoskeletal conditions are the second biggest contributor for disability around the world, with low back pain being the single driving reason for disability worldwide. Musculoskeletal conditions involve in excess of 150 diagnoses that influence the loco motor framework. Musculoskeletal disorders are predominant over the life-course and most ordinarily influence individuals from pre-adulthood through to elderly. Global musculoskeletal disorders therapeutics market for the five markers which incorporates rheumatoid joint pain, osteoporosis, osteoarthritis, low back pain and muscular dystrophy was esteemed at $33.4 billion at 2010, showing a CAGR of 5.7% and will post a humble CAGR of around 4% by 2020.

Musculoskeletal Oncology | Musculoskeletal Infections | Osteoarthritis | Rheumatoid arthritis | Osteomalacia | Musculoskeletal Physiotherapy

Track 5: Osteoporosis and Endocrine disorders

Endocrine issue constitute the most successive reason for optional osteoporosis in people, since endocrine infections are normal e.g., diabetes mellitus, hyperparathyroidism, and hyperthyroidism, they ought to be considered in the differential finding and administration of osteopenia. Several endocrine problems are known to be related with a high risk for osteoporosis. Among bone disorders that endocrinologists help to treat, osteoporosis is the most well-known. Frequently, endocrinologists likewise look after patients with osteoporosis that is optional to hyperparathyroidism or kidney failure among other metabolic and hormonal conditions that can likewise prompt Osteoporosis. Recognizing a hidden reason and redressing hypo-or hyper function of an endocrine organ, notwithstanding, can frequently prompt an expansion in bone mineral thickness. Peak bone mass, characterized as the maximum bone density an individual will have, is come to in the vicinity of 16 and 25 years old. Hormonal balance is one of the variables important to achieve peak bone mass. Low levels of hormones at youth and youthful adulthood are related with less bone mass. This audit centres around late examinations on hormonal disarranges that influence the skeleton .An excess of thyroid hormone can expand bone loss and consequently results for osteoporosis. The worldwide endocrine testing market was esteemed at US$ 7,359.4 Mn in 2016, and is relied upon to achieve US$ 14,758.6 Mn by 2025, growing at a CAGR of 7.9% from 2017 to 2025.

Hormone Replacement Therapy | Endocrine Disorders Conferences | Diagnostic Centers | Osteoporosis Treatment Market

Track 6: Osteoporosis and Geriatrics

With socio-economic development in many developing countries and rapid ageing of the population, osteoporosis has become one of the most prevalent and costly health problems in these regions. Europe is the second largest market for bone density test. As people get older, they begin to lose more bone than they build. The worldwide osteoporosis drugs market is seeing imperative development by virtue of developing geriatric population combined with changing ways of life impinging bone health. Pervasiveness of osteoporosis is more typical with age. Around 15% of white individuals in their 50s and 70% of those more than 80 are influenced by osteoporosis diseases. It is more typical in women than men. Calcium supplementation has been appeared to positively affect bone mineral density in postmenopausal women. Supplementation with both vitamin D and calcium, contrasted and calcium alone, decreased body influence in elderly women, recommending that redress of vitamin D lack may enhance neuromuscular function thus reduce the affinity to fall. In an examination in elderly people, higher dietary protein admission was related with a lower rate of age-related bone loss.

Geriatric Conferences | Geriatric Rheumatology | Geriatric Physician | Geriatric Rehabilitation | Gerontological Nursing | Paralysis Agitans | Renal Osteodystrophy

Track 7: Osteoporosis and Nutrition

Nutrition is one of the fundamental factors controlling bone growth, development throughout the life time. Nutrition and bone, muscle and joint health are firmly related. A healthy diet can help stop and manage osteoporosis and related musculoskeletal disorders by aiding the formation and support of bone. Two of the most imperative supplements are calcium and vitamin D. Calcium is a noteworthy building-square of bone tissue, the skeleton houses 99% of the body's calcium stores. Vitamin D is key at it helps your body to ingest calcium. There are various nutrition’s, supplements and vitamins, other than calcium and vitamin D, that assistance to counteract osteoporosis and add to bone, muscle and joint wellbeing, including protein, foods grown from the ground, and different vitamins and minerals. Late research has discovered that olive oil, soy beans, blueberries and foods wealthy in omega-3s, similar to angle oil and flaxseed oil may likewise have bone boosting benefits.

Vitamins for Bone Health | Vitamin D Supplements | Calcium | Rheumatoid Arthritis Diet | Nutrition Conferences

Track 8: Paediatric Bone Health

During childhood bone formation exceeds reabsorption and remodelling is intense. In youth, both osteopenia and osteoporosis have a tendency to be asymptomatic. The essential indication of osteoporosis is the occurrence of fractures after light traumas or during daily activity. In childhood, osteoporosis is generally secondary to chronic diseases, and primary osteoporosis is a very rare entity. The primary driver of youth osteoporosis are infections of the stomach related framework, nutritious ailments, neoplastic diseases, renal sicknesses, illnesses of the connective tissue, lung ailments, endocrine ailments, neuropsychiatric ailments. Satisfactory levels of calcium intake can amplify the beneficial outcome of physical activity on bone health during the development time of youngsters. Osteoporosis is in effect progressively perceived in paediatric practice as an outcome of a few components. Children of individuals with an osteoporotic fracture are more likely to have low BMD themselves.

Paediatric Orthopaedics | Juvenile Osteoporosis | Paediatric Bone Health Meetings | paediatrician | Rickets | Osteogenesis Imperfecta

Track 9: Genetics of Osteoporosis

Osteoporosis is a common disease with a strong genetic component characterised by reduced bone mass and an increased risk of fragility fractures. As of late, some advance has been made in understanding the hereditary premise of osteoporosis. Hereditary components add to osteoporosis by impacting bone mineral thickness as well as bone size, bone quality, and bone turnover. Meta-analysis has been utilized to characterize the part of a few competitor qualities in osteoporosis. Some quantitative characteristic loci that control bone mass recognized by linkage contemplates in people and test creatures have been repeated in different populaces. Qualities that reason monogenic bone illnesses additionally add to direction of bone mass in the ordinary population. Far reaching affiliation thinks about and useful genomics approaches have as of late connected to hereditary investigations of osteoporosis. On the whole, more than 60 loci have been related with BMD with 15 loci related with fracture risk. Later on, single quality as well as the whole quality systems associated with osteoporosis and control of bone mass will methodically be found through integrative genomics.

Osteogenesis | Recombinant Osteolectin | Osteoporosis Risk Gene Variants | Skeletal Heterogeneity | Genetic Determinants of Osteoporosis

Track 10: Osteoporosis and Cancer

Nearly all cancers can have significant negative effects on the skeleton. Cancer is a major risk for both generalized and local bone loss, with bone loss as  assessed by bone mineral density BMD testing substantially higher in cancer patients than in the general population, independent of cancer type. This is due to both the direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. The skeleton is additionally the most well-known site of metastatic infection, as malignancy cells developing inside bone prompt osteoblasts and osteoclasts to create factors which invigorate encourage disease development. Although cancer is not exclusively a disease of aging, cancer more commonly occurs in older individuals. Likewise, aging in both men and women is associated with increased rates of osteoporosis and fractures. Anti-resorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients. Non-pharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

Osteosarcoma | Osteochondroma | Musculoskeletal Oncology | Bone Tumors | Tumor-Induced Bone Resorption

Track 11: Osteoporosis and Women

Generally bone loss is a normal part of aging in both men and women, but it is estimated that women faces greater risk for osteoporosis than men. Estrogen is a hormone that helps regulate a woman’s reproductive cycle. At the same time, it plays a major role in keeping bones strong and healthy, in both men and women. While premenopausal women have more estrogen than men, they will experience dramatic drops in estrogen production due to menopause, and are more likely to experience bone loss and osteoporosis at that time. So, as women starts with low bone density than men, they have the greater chance of losing bone density earlier than men as age increases. It is also been proved that osteoporosis affects about 200 million women every year across the globe. In Europe Osteoporosis is assessed to influence 200 million women overall roughly one-tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and 66% of women aged 90.Worldwide, 1 out of 3 women over age 50 will encounter osteoporotic fractures.

Gynaecologists | Estrogen Osteoporosis | Postmenopausal Osteoporosis | Physical Activity for Women | Wearable Air Bags

Track12: Osteoporosis Medications

The worldwide osteoporosis drugs market was worth $8,835.4 million of every 2015 and it is required to develop at a CAGR of 3.8% during 2016-2022. Bisphosphonates are the most ordinarily recommended medication for treatment and prevention of osteoporosis. Additionally, expanding the predominance of osteoporosis in postmenopausal women, developing mindfulness about osteoporotic care, and expanding interest in sedate disclosure and improvement are likewise driving the development of the market. The European osteoporosis drugs market is developing at a critical rate mostly because of growing aging population, expanding predominance of osteoporosis in postmenopausal women and expanding awareness of osteoporosis.

Osteoporosis Medication Conferences | Osteoporosis Drugs Market | Calcitonin in Osteoporosis | Arthritis Medication

Track13: Orthopaedic Surgery and Sports Medicine

Research Orthopedics and Sports Medicine practice is a general orthopedic practice that looks after an extensive variety of care, both careful and non-careful for counteractive action, evaluation, treatment and restoration of numerous bone and joint injuries. Orthopedic inserts are made to supplant or bolster an absent or harmed bone or joint. These inserts are proposed to treat the disfigurements, stabilize body posture, and re-establish the typical skeletal capacity. Worldwide Orthopedic Implant Market was esteemed at $47,261 million out of 2016, and is relied upon to earn $74,796 million by 2023, enrolling a CAGR of 6.8% amid the figure time frame 2017-2023. Worldwide Orthopedic Device Market to reach $44 Billion by 2022, attributable to different variables that are empowering it to advance at a CAGR of 4.9% from 2019 to 2022. The worldwide games medication showcase is relied upon to achieve USD 12.5 billion by 2025.

Fitness Training | Sports physiotherapy | Prosthetics | Osteoporosis Assistive Devices | Ambulatory Surgical Centers | Orthopedic Fixation Devices | Orthopedic Surgeon

Market Analysis

Market Research

Osteoporosis is a global public health problem currently affecting more than 200 million people worldwide. Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Worldwide, osteoporotic fractures occurring are 8.9 million (89 cores) per year. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. Patients with osteoporosis and osteopenia are at increased risk of suffering fractures, due to a loss in bone strength. These fractures place a considerable burden on public health systems, and significant unmet need remains for osteoporosis therapies that are safer and more efficacious, particularly in reducing the risk of non-vertebral fractures e.g., hip fractures. The launch of several key new therapies will lead to significant market changes over the 2016-2026 forecast periods. The global osteoporosis drugs market was valued at US$8.4 billion in 2013 and is expected to be valued at US$8.9 billion by 2020. The global osteoporosis drugs market is forecast to grow at a 1.2% CAGR in the time period of 2013-2020.


Scope and Importance:

A recent report issued by the International Osteoporosis Foundation estimates that more than 22 million women aged between 50–84 years in the European Union (EU) have osteoporosis. Postmenopausal women are at greatest risk of broken bones due to the hormonal changes that occur at menopause which result in rapid loss of bone mass. For approximately one in three women in the EU, excessive bone loss together with other factors, leads to osteoporosis-related fragility fractures. The cost of fragility fractures to European healthcare systems is in excess of €37 billion each year. As a result of an ageing population in the EU the number of men and women with osteoporosis is expected to increase by 23% from 2010 to 2025, when an estimated 33.9 million people will have osteoporosis.


Why Spain?

Coming to the Spain within period of 14 years from the year 2003 to 2017, there is a gradual increase of 74 % in the case of fractures; out of which women are 64% compared to the men 19%. In 2018 approximately 206,000 new fragility fractures; number of people aged 50+ with osteoporosis, approximately 2,540,000; economic burden of new and prior fractures € 3,842 million each year; by 2025 burden will increase by 30 % to € 4.68 billion. This increase occurred mainly in women (64%) compared to men (19%). 13% of patients who have suffered a fracture die after 3 months and this figure rises to 38% after 24 months. The cost of osteoporosis, including pharmacological intervention in the EU in 2018 was estimated at €47 billion – out of which:  Costs of treating incident fractures represented 76%, Pharmacological prevention 10% and Long-term fracture care 39%. The total health burden osteoporosis in the EU was estimated at 1,480,000 lost Quality Adjusted Life Years for the EU.

Companies dealing with Osteoporosis Drugs

Pfizer, Inc., Eli Lily And Company, F. Hoffmann La Roche, Novartis Ag, Merck & Co. Inc., Amgen, Inc., Radius Health, Inc., Teva Pharmaceutical Industries Ltd, Glaxosmithkline Plc

Companies dealing with Orthopedic Devices

DePuy Synthes, DJO Global, Medtronic, Strykar, Smith & Nephew, Zimmer Biomet, Acumed, Aesculap Implant Systems, AlloSource, Alphatec Spine, Camber Spine technologies, Intelligent Implant Systems, Nextremity Solutions, NovaBone
NuTech Medical, Vilex, Virak Orthopedics

Learn More

Top Osteoporosis Univeristies Worldwide:

Europe Osteoporosis Universities:

USA Osteoporosis Universities:

Asia Osteoporosis Universities:

Europe Osteoporosis Societies:

USA Osteoporosis Societies:

Asia Osteoporosis Societies:

Osteoporosis Associations:

Osteoporosis Hospitals in Europe:

Osteoporosis Hospital in USA:

Osteoporosis Hospitals in Asia:

Europe Osteoporosis Conferences:

USA Osteoporosis Conferences:

Asia Pacific Osteoporosis Conferences:

Leading Osteoporosis Companies in Europe:

Leading Osteoporosis Companies in USA:

Leading Osteoporosis Companies in Asia:

Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!